ClinicalTrials.gg
CompletedNCT02091206Updated Sep 28, 2022Results posted

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

A Phase 2 interventional study of GWP42003-P 5 mg/kg/day Dose and Placebo control in Epilepsy and Dravet Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionEpilepsies, MyoclonicRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Myoclonic
Why
  1. The study's listed conditions name Epilepsies, Myoclonic, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
4 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing cannabidiol in Epilepsies, Myoclonic — 1 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Epilepsies, Myoclonic.

Enrollment
7th of 14
34 · median 30
Started
2014
with 1 other
Phase 2
Only one
of the 14
Registered
1st of 14
by date
Lead sponsor
6 of 14
Jazz Pharmaceuticals

Among the 14 studies testing cannabidiol in Epilepsies, Myoclonic, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is the only one in phase 2, and was the 1st registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

1 of the 14 studies testing cannabidiol in Epilepsies, Myoclonic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 4 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cannabidiol in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

To evaluate the safety and pharmacokinetics (PK) of multiple doses of GWP42003-P compared with placebo in children with Dravet syndrome.

Read the detailed description

This multi-center study consisted of 2 parts: Part A and Part B. Only Part A is described in this record. Part A was a randomized, double-blind 21-day treatment study period. Participants were randomized to one of 3 doses of active drug or placebo at a 4:1 ratio.

Participants who satisfied all inclusion and none of the exclusion criteria were assigned a unique participant number and then began a 28-day baseline observation period.

Eligible participants were then randomly assigned to receive one of 3 dose levels of GWP42003-P: 5 milligrams (mg) per kilogram (kg) per day, 10 mg/kg/day, 20 mg/kg/day, or matching placebo.

There were three groups of ten participants. In each group, participants were randomly assigned so that eight participants received active treatment and two participants received placebo. Participants received GWP42003-P or placebo for a 21-day exposure period, which consisted of a titration period, followed by a stable dose period.

A PK assessment took place after the first single dose of GWP42003-P. There was a second PK assessment after 21 days of consecutive dosing with GWP42003-P. Participants who took clobazam (CLB) as an adjunctive treatment were asked to take their usual dose 2 hours prior to attending the clinic. The same recommendation was made for other concomitant antiepileptic drugs (AEDs), if applicable. This was so that the pre-treatment (with GWP42003-P) plasma concentrations of CLB, its major metabolite N-desmethylclobazam, and any other concomitant AEDs could be measured, and the impact of GWP42003-P treatment on these levels evaluated. Interim clinic visits to (primarily) evaluate safety and adherence to the titration regimen took place at 7 and 14 days of treatment.

After 21 days of treatment, all participants commenced a 10-day down-titration taper period. An independent Data Safety Monitoring Committee reviewed unblinded safety and PK data and recommended the target dose (up to 20 mg/kg/day) for Part B of the study and for an open label extension study. Once the safety review of Part A data had taken place, participants had the option of entering the open label extension study.

A follow-up telephone call was made 28 days after the end of dosing for participants who did not enter the open label extension study within this time-frame.

Throughout the 21-day treatment period and the 10-day taper period, there were regular safety telephone calls (approximately every 2 days) to check participant status. Weekly safety telephone calls were made during the 28-day follow-up period.

03

Conditions studied

  • Epilepsy
  • Dravet Syndrome

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

In context

Epilepsies, Myoclonic Reclassified

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

This study's enrollment of 34 is close to the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.

Browse Epilepsies, Myoclonic studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Compared within Epilepsies, Myoclonic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants were male or female aged between 4 and 10 years (inclusive).
  • Participants had a documented history of Dravet Syndrome that was not completely controlled by AEDs.
  • Participants took one or more AEDs at a dose which had been stable for at least 4 weeks.
  • Participants had experienced fewer than 4 convulsive seizures (tonic-clonic, tonic, clonic, atonic seizures) during the 28-day baseline period.
  • All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation [VNS]) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study. The ketogenic diet and VNS treatments were not counted as an AED.

Key Exclusion Criteria:

  • Participants had unstable medical conditions other than epilepsy.
  • Participants had clinically relevant abnormalities in the 12-lead measured at screening or randomization.
  • Participants were currently using or had in the past used recreational or medicinal cannabis, or synthetic CBD based medications (including Sativex®) within the 3 months prior to study entry and were unwilling to abstain for the duration for the study.
  • Participants had any known or suspected to cannabinoids or any of the of the IMP.
  • Participants who had been part of a clinical trial involving another product in the previous 6 months.
  • There were plans for the participants to travel outside their country of residence during the study.
  • Participants were previously randomized into this study. In particular, participants participating in Part A of the study cannot enter Part B.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    GWP42003-P 5 mg/kg/day Dose

    Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P 5 mg/kg/day Dose

  • Experimental
    GWP42003-P 10 mg/kg/day Dose

    Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P 10 mg/kg/day Dose

  • Experimental
    GWP42003-P 20 mg/kg/day Dose

    Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P 20 mg/kg/day Dose

  • Placebo comparator
    Placebo

    Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.

    Drug: Placebo control

Interventions

  • DrugGWP42003-P 5 mg/kg/day Dose

    Drug page: Cannabidiol

    GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.

    Also known as: Cannabidiol, Epidiolex

  • DrugPlacebo control

    Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

    Also known as: Placebo

  • DrugGWP42003-P 10 mg/kg/day Dose

    Drug page: Cannabidiol

    GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.

    Also known as: Cannabidiol, Epidiolex

  • DrugGWP42003-P 20 mg/kg/day Dose

    Drug page: Cannabidiol

    GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.

    Also known as: Cannabidiol, Epidiolex

07

What researchers measure

Primary outcomes

  1. Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event (AE) with an onset date on or after the first dose of IMP. If an AE had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through the Safety Follow-up Visit (Day 60) is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Adverse Events module.

    Time frame: Baseline (Day 1) through Safety follow-up visit (Day 60)

Secondary outcomes

  1. Area Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22

    AUC0-t for CBD and its major metabolites, 6-hydroxy-CBD (6-OH-CBD), 7-hydroxy-CBD (7-OH-CBD), and 7-carboxy-CBD (7-COOH-CBD) were calculated using blood samples collected before and after IMP dosing on Days 1 and 22. One sample was collected predose, 2 to 3 hours postdose, and 4 to 6 hours postdose for CBD and its metabolites. Results are presented for participants who received GWP42003-P at 5, 10, or 20 mg/kg/day during the study and for participants with a numeric result for the given evaluation.

    Time frame: Predose and 2-6 hours postdose on Days 1 and 22

  2. Mean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations

    Plasma concentrations of CLB and N-CLB were measured on Days 1 and 22. Participants were instructed to take their daily dose of CLB 2 hours prior to the anticipated pre-IMP blood specimen collection on both days. Blood samples were collected prior to administration of IMP. Results are presented for a subgroup of participants who took CLB during the study and had PK samples analyzed at both PK sampling visits (Days 1 and 22).

    Time frame: Predose on Days 1 and 22

08

Results

Posted Jul 19, 2018
Limitations and caveats
Analytical issues for 7-OH-CBD related to reference material batch used during analysis. Data are qualitative.

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
Started10897
Safety analysis set10897
Completed10787
Not completed0110
Withdrew: Adverse event0100
Withdrew: Met withdrawal criteria0010
Taper Period
Participant flow — Taper Period
MilestoneGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
Started10787
Completed9785
Not completed1002
Withdrew: Participant refused study drug1001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryNumber Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as an adverse event (AE) with an onset date on or after the first dose of IMP. If an AE had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through the Safety Follow-up Visit (Day 60) is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Adverse Events module.

Time frame:
Baseline (Day 1) through Safety follow-up visit (Day 60)
Reported as:
Count of participants · Participants
Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)
ParticipantsGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)2101
SecondaryArea Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22

AUC0-t for CBD and its major metabolites, 6-hydroxy-CBD (6-OH-CBD), 7-hydroxy-CBD (7-OH-CBD), and 7-carboxy-CBD (7-COOH-CBD) were calculated using blood samples collected before and after IMP dosing on Days 1 and 22. One sample was collected predose, 2 to 3 hours postdose, and 4 to 6 hours postdose for CBD and its metabolites. Results are presented for participants who received GWP42003-P at 5, 10, or 20 mg/kg/day during the study and for participants with a numeric result for the given evaluation.

Time frame:
Predose and 2-6 hours postdose on Days 1 and 22
Reported as:
Geometric mean · hours * nanograms/mL
Area Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22
hours * nanograms/mLGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day Dose
Day 1 CBD70.61 ± 20.3866.35 ± 120.873.69 ± 96.64
Day 22 CBD240.8 ± 100.8721.8 ± 79.92962.6 ± 93.43
Day 1 6-OH-CBD3.27 ± 1322.79 ± 87.75.16 ± 57.2
Day 22 6-OH-CBD9.33 ± 11926.3 ± 82.958.6 ± 90.1
Day 1 7-OH-CBD21.9 ± 57.018.4 ± 29930.2 ± 105
Day 22 7-OH-CBD131 ± 107244 ± 120508 ± 96.0
Day 1 7-COOH-CBD297 ± 97.3125 ± 1750195 ± 573
Day 22 7-COOH-CBD4190 ± 81.209220 ± 17815500 ± 148
SecondaryMean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations

Plasma concentrations of CLB and N-CLB were measured on Days 1 and 22. Participants were instructed to take their daily dose of CLB 2 hours prior to the anticipated pre-IMP blood specimen collection on both days. Blood samples were collected prior to administration of IMP. Results are presented for a subgroup of participants who took CLB during the study and had PK samples analyzed at both PK sampling visits (Days 1 and 22).

Time frame:
Predose on Days 1 and 22
Reported as:
Number · percent change
Mean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations
percent changeGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
% change in CLB-1.218.029.615.1
% change in N-CLB258.7170.7228.9-5.6

Adverse events

Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 5 mg/kg/Day Dose—1/10 (10%)8/10 (80%)
GWP42003-P 10 mg/kg/Day Dose—2/8 (25%)5/8 (62.5%)
GWP42003-P 20 mg/kg/Day Dose—1/9 (11.1%)7/9 (77.8%)
Placebo—1/7 (14.3%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
PyrexiaGeneral disorders0/102/80/90/7
Viral InfectionInfections and infestations0/100/80/91/7
ConvulsionNervous system disorders0/101/80/91/7
Rash Maculo-papularSkin and subcutaneous tissue disorders0/101/80/90/7
Parvovirus InfectionInfections and infestations0/100/81/90/7
Status EpilepticusNervous system disorders1/100/80/90/7
Most frequent other events
Showing 10 of 53
Most frequent other events
EventGWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlacebo
Decreased appetiteMetabolism and nutrition disorders0/101/84/90/7
SomnolenceNervous system disorders2/103/80/91/7
PyrexiaGeneral disorders3/101/80/90/7
Abnormal behaviourPsychiatric disorders3/100/80/90/7
FatigueGeneral disorders0/100/81/92/7
GastroenteritisInfections and infestations1/100/80/92/7
Abdominal Pain UpperGastrointestinal disorders0/100/82/90/7
SedationNervous system disorders2/100/82/90/7
AtaxiaNervous system disorders2/100/81/90/7
DiarrhoeaGastrointestinal disorders0/100/80/91/7

Baseline characteristics

Safety Analysis Set: included all participants randomized to treatment who received at least 1 dose of IMP. Participants were analyzed according to the treatment they received. Only participants for whom it had been confirmed that they did not take any IMP were excluded from the safety analysis set.

Age, Continuous
Age, Continuous(Years)GWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlaceboTotal
Mean7.150 ± 1.89557.368 ± 2.12298.671 ± 1.79576.978 ± 0.94767.568 ± 1.8300
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 5 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DoseGWP42003-P 20 mg/kg/Day DosePlaceboTotal
Female556218
Male533516
09

Study locations

11 sites
  • Miami, Florida 33155, United States
  • Atlanta, Georgia 30328, United States
  • Chicago, Illinois 60611, United States
  • Iowa City, Iowa 52242, United States
  • Boston, Massachusetts 02114, United States
  • Winston-Salem, North Carolina 27408, United States
  • Columbus, Ohio 43205, United States
  • Houston, Texas 77030, United States
  • Edinburgh, EH9 1LF, United Kingdom
  • Liverpool, L12 2AP, United Kingdom
  • London, WC1N 3JH, United Kingdom
10

References and documents

Publications

  • Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. PubMed 29540584 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Mar 2015, 4 months.

Results were first posted in Jul 2018, 3 years 4 months after primary completion. A results delay was requested in Jun 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 19, 2014
StartActual
Oct 22, 2014
Primary completionActual
Mar 9, 2015
CompletionActual
Mar 9, 2015
Results delay requested
Jun 17, 2016
Results first posted
Jul 19, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02091206
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Oct 22, 2014
Primary completion
Mar 9, 2015
Completion
Mar 9, 2015
Results posted
Jul 19, 2018
Last update
Sep 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion